2025年上半年,再鼎医药净亏损约为8916万美元,较去年同期收窄33.33%。公司总收入达到2.16亿美元,同比增长15.35%。这一业绩反映了公司在控制亏损方面的积极进展。
Source Link2025年上半年,再鼎医药净亏损约为8916万美元,较去年同期收窄33.33%。公司总收入达到2.16亿美元,同比增长15.35%。这一业绩反映了公司在控制亏损方面的积极进展。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.